Nabi Biopharmaceuticals

Nabi Biopharmacetuicals was a drug development company in Rockville, Maryland.

Its principal product was NicVAX (also known as 3′AmNic-rEPA), a nicotine conjugate vaccine intended to reduce physical addiction to nicotine.

The drug was developed with help from the U.S. National Institute of Drug Abuse, and showed promise in early studies, however, two successive phase III trials of the drug in 2009 and 2011 failed.

On Thursday, November 8, 2012 the business combination of Nabi Biopharmaceuticals and Biota Holdings Limited became effective to create Biota Pharmaceuticals, Inc. (NASDAQ: BOTA)

...
Wikipedia